Mesothelioma Chemotherapy: Comparison of Cisplatin and Carbopla

Mesothelioma Chemotherapy: Comparison of Cisplatin and Carbopla

A mesothelioma article recently published in scientific journals Lung Cancer that examines the benefits and costs of Cisplatin and Pemetrexed in combination with Carboplatin and Pemetrexed for mesothelioma

PA Photos Mesothelioma Exposure AsbesKemoterapi combination Cisplatin and Pemetrexed is one of several choices of chemotherapy that has proven quite successful for treating patients with malignant pleural mesothelioma / malignant pleural mesothelioma (MPM), but this combination can be very toxic to the body. There is no treatment and treatment for malignant mesothelioma cancer without undesirable side effects.
In the journal the researchers noted that "there are two phases of a randomized study in phase III shows the benefit for the prognosis of mesothelioma with the use of antifolates such as raltitrexed or Pemetrexed, in combination with cisplatin. The study has shown an absolute improvement in overall survival on average 2.6 and 2.8 months, compared with single treatment for cisplatin. This makes a lot of institutions using Cisplatin and Pemetrexed as the standard palliative chemotherapy treatment for malignant pleural mesothelioma. "

Unfortunately, the combination of Cisplatin and Pemetrexed produce unwanted toxic effects and it encourages researchers to study other chemotherapy drugs in combination with Pemetrexed. The researchers said, "Recently, two phase II trials have evaluated the efficacy of Carboplatin and Pemetrexed will in MPM. Both studies showed overall response rates 18.6 and 25%, with a survival rate average of 12.7 and 14 months. As a continuation of these results, we have retrospectively analyzed in patients with MPM who were treated with Carboplatin and Pemetrexed in our institution. "

In an effort to find a combination of chemotherapy mesothelioma with minimal toxicity and side effects, the researchers investigated further by replacing Cisplatin with Carboplatin when paired with Pemetrexed. By using a retrospective approach, researchers evaluated 49 cases malignant pleural mesothelioma who were given a combination of Carboplatin and Pemetrexed and compare the results with data of cisplatin combination chemotherapy with Pemetrexed.

The level of disease control (which is known by the absence of progressive signs of mesothelioma over CT scans) for the patients was 69 percent, and partial response and stable disease percentage of 28 percent and 41 percent. Clinical improvement shown in figure 69 percent, the majority of patients reported an increase in profits after two cycles of chemotherapy. Toxicity is generally low and better than the toxicity of cisplatin with Pemetrexed.

The average time of treatment failure was 4.6 months. The average overall survival in this study is 14 months, compared with the cisplatin-pemetrexed for 12.1 months. The researcher argues, "In conclusion, our data show a combination of Carboplatin and Pemetrexed may be an option in the treatment of mesothelioma, particularly in patients who have problems with the use of cisplatin."                                                          BY JEVUSKA


No comments:

Post a Comment